Meanwhile, it was discovered that all high-frequency mutation genes in the American population were within the screening scope recommended by the NCCN guidelines, while the high-frequency mutation genes in the Chinese cohort of ovarian cancer, such as MC1R, PRKDC, KIF1B, FANCM, FANCI, PRSS1, and SDHA, were not included in the scope of the NCCN guidelines, indicating that the NCCN guidelines based on the European and American populations were not suitable for ovarian cancer genetic screening in the Chinese population. This evidence concerns the gene PRSS1 and ovarian cancer.